Fiala, O. Et Al. 2025. Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study. Clinical and Experimental Metastasis , vol.42, no.2 .

Fiala, O., Buti, S., Fujita, K., de Liaño, A. G., Fukuokaya, W., Kimura, T., ... Yanagisawa, T.(2025). Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study. Clinical and Experimental Metastasis , vol.42, no.2.

Fiala, Ondřej Et Al. "Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study," Clinical and Experimental Metastasis , vol.42, no.2, 2025

Fiala, Ondřej Et Al. "Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study." Clinical and Experimental Metastasis , vol.42, no.2, 2025

Fiala, O. Et Al. (2025) . "Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study." Clinical and Experimental Metastasis , vol.42, no.2.

@article{article, author={Ondřej Fiala Et Al. }, title={Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study}, journal={Clinical and Experimental Metastasis}, year=2025}